PHARMAC is pleased to announce the approval of a proposal to fund adalimumab and etanercept to treat pyoderma gangrenosum in the community and hospital setting.

This decision means that funded access to etanercept and adalimumab will be widened via Special Authority in Section B and restrictions in Section H of the Pharmaceutical Schedule to include the treatment of pyoderma gangrenosum from 1 July 2014.

For more details, go to: http://www.pharmac.health.nz/news/notification-2014-06-17-tnf-inhibitors/